Diffuse Large B-Cell Lymphoma, NOS · Loncastuximab tesirine monotherapy (R/R DLBCL, 3L+; LOTIS-2)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-LONCASTUXIMAB-TESIRINE`

ID	`IND-DLBCL-3L-LONCASTUXIMAB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-DLBCL-NOS`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-LOTIS-2-CAIMI-2021` `SRC-NCCN-BCELL-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. 3L+ standard-track option for r/r DLBCL when CAR-T not feasible. Off-the-shelf alternative to bispecifics. REG-LONCASTUXIMAB-TESIRINE wired 2026-04-30.

Used By

Algorithms

ALGO-DLBCL-2L - ALGO-DLBCL-2L
ALGO-DLBCL-3L - ALGO-DLBCL-3L

Regimen

REG-LONCASTUXIMAB-TESIRINE - Loncastuximab tesirine monotherapy (R/R DLBCL, 3L+; LOTIS-2)